These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27662841)

  • 21. Higher IGFBP3 is associated with increased incidence of colorectal cancer in older men independently of IGF1.
    Chan YX; Alfonso H; Paul Chubb SA; Ho KKY; Gerard Fegan P; Hankey GJ; Golledge J; Flicker L; Yeap BB
    Clin Endocrinol (Oxf); 2018 Feb; 88(2):333-340. PubMed ID: 29044573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of association between risk of biliary tract cancer and circulating IGF (Insulin-like Growth Factor) -I, IGF-II or IGFBP-3 (IGF-binding Protein-3): A nested case-control study in a large scale cohort study in Japan.
    Yagyu K; Kikuchi S; Lin Y; Ishibashi T; Obata Y; Kurosawa M; Ito Y; Watanabe Y; Inaba Y; Tajima K; Nakachi K; Tamakoshi A;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():63-7. PubMed ID: 20553084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study.
    Otani T; Iwasaki M; Sasazuki S; Inoue M; Tsugane S;
    Int J Cancer; 2007 May; 120(9):2007-12. PubMed ID: 17266031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time spent walking or exercising and blood levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3): A large-scale cross-sectional study in the Japan Collaborative Cohort study.
    Wakai K; Suzuki K; Ito Y; Watanabe Y; Inaba Y; Tajima K; Nakachi K; Tamakoshi A;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():23-7. PubMed ID: 20553077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: the Health In Men Study.
    Yeap BB; Chubb SA; McCaul KA; Ho KK; Hankey GJ; Norman PE; Flicker L
    Eur J Endocrinol; 2011 May; 164(5):715-23. PubMed ID: 21378090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and the risk of fibrocystic breast conditions among Chinese women.
    Chen C; Doherty JA; Lewis SK; Ray RM; Gao DL; Stalsberg H; Feng Z; Thomas DB
    Int J Cancer; 2006 May; 118(9):2303-9. PubMed ID: 16331609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Prospective Association Between Plasma Concentrations of Cellular Growth Factors and Risk of Heart Failure Mortality in Japanese Population.
    Eshak ES; Maruyama K; Iso H; Tamakoshi A
    J Epidemiol; 2019 Mar; 29(3):104-109. PubMed ID: 30078811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating IGF system and treatment outcome in epithelial ovarian cancer.
    Huang YF; Cheng WF; Wu YP; Cheng YM; Hsu KF; Chou CY
    Endocr Relat Cancer; 2014 Apr; 21(2):217-29. PubMed ID: 24273235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
    Tajtakova M; Pidanicova A; Valansky L; Lachvac L; Nagy V; Sivonova M; Dobrota D; Kliment J; Petrovicova J
    Neoplasma; 2010; 57(2):118-22. PubMed ID: 20099974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Relation to the Risk of Type 2 Diabetes Mellitus: Results From the EPIC-Potsdam Study.
    Drogan D; Schulze MB; Boeing H; Pischon T
    Am J Epidemiol; 2016 Mar; 183(6):553-60. PubMed ID: 26880678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.
    Palmqvist R; Hallmans G; Rinaldi S; Biessy C; Stenling R; Riboli E; Kaaks R
    Gut; 2002 May; 50(5):642-6. PubMed ID: 11950809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating IGF1 and IGFBP3 in relation to the development of β-cell autoimmunity in young children.
    Peet A; Hämäläinen AM; Kool P; Ilonen J; Knip M; Tillmann V;
    Eur J Endocrinol; 2015 Aug; 173(2):129-37. PubMed ID: 25947142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.
    Patel D; Ellis R; Howard B; Boufraqech M; Gara SK; Zhang L; Quezado MM; Nilubol N; Kebebew E
    Ann Surg Oncol; 2014 Oct; 21(11):3541-7. PubMed ID: 24833102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men.
    Yeap BB; Chubb SA; Ho KK; Setoh JW; McCaul KA; Norman PE; Jamrozik K; Flicker L
    Eur J Endocrinol; 2010 Feb; 162(2):249-57. PubMed ID: 19917654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population.
    Cheng I; DeLellis Henderson K; Haiman CA; Kolonel LN; Henderson BE; Freedman ML; Le Marchand L
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3660-6. PubMed ID: 17566087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.
    Schumacher FR; Cheng I; Freedman ML; Mucci L; Allen NE; Pollak MN; Hayes RB; Stram DO; Canzian F; Henderson BE; Hunter DJ; Virtamo J; Manjer J; Gaziano JM; Kolonel LN; Tjønneland A; Albanes D; Calle EE; Giovannucci E; Crawford ED; Haiman CA; Kraft P; Willett WC; Thun MJ; Le Marchand L; Kaaks R; Feigelson HS; Bueno-de-Mesquita HB; Palli D; Riboli E; Lund E; Amiano P; Andriole G; Dunning AM; Trichopoulos D; Stampfer MJ; Key TJ; Ma J
    Hum Mol Genet; 2010 Aug; 19(15):3089-101. PubMed ID: 20484221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IGF1 and risk of additional breast cancer in the WHEL study.
    Al-Delaimy WK; Flatt SW; Natarajan L; Laughlin GA; Rock CL; Gold EB; Caan BJ; Parker BA; Pierce JP
    Endocr Relat Cancer; 2011 Apr; 18(2):235-44. PubMed ID: 21263044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.
    Terry KL; Tworoger SS; Gates MA; Cramer DW; Hankinson SE
    Carcinogenesis; 2009 Dec; 30(12):2042-6. PubMed ID: 19858071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ω-3 fatty acid differentially modulated serum levels of IGF1 and IGFBP3 in men with CVD: a randomized, double-blind placebo-controlled study.
    Gholamhosseini S; Nematipour E; Djazayery A; Javanbakht MH; Koohdani F; Zareei M; Djalali M
    Nutrition; 2015 Mar; 31(3):480-4. PubMed ID: 25701338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.